Injected weight-loss drugs Wegovy, from Novo Nordisk, and Eli Lilly's Zepbound have U.S. list prices of over $1,000 a month.

Tirzepatide (Zepbound) came out on top against semaglutide (Wegovy) for treating obesity in the head-to-head SURMOUNT-5 trial ...

A new study found users of one drug lost almost 50 percent more weight that users of Wegovy. People taking Eli Lilly’s ...

The popular weight loss medications produced different results in patients who participated in a trial, and here’s what ...

The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the ...

CVS Caremark decided to stop offering one product in favor of another for weight loss, the latest example of ...

The head-to-head examination of these weight loss drugs provides doctors with 'robust' data on their effectiveness.

Eli Lilly announced that its obesity therapy Zepbound delivered superior outcomes versus Novo Nordisk’s Wegovy across five ...

While the primary target for these medication is weight loss, it’s not the only metric by which the drugs should be evaluated ...

Wegovy and Zepbound are part of a wave of obesity medications known as GLP-1 receptor agonists that have soared in popularity ...

Tirzepatide (trade name Zepbound) promoted greater weight loss in individuals with obesity than did semaglutide (trade name Wegovy) in a clinical trial that compared the safety and efficacy of the ...